Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab plus Anlotinib vs Chemotherapy in Advanced Gastric Cancer
NCT04385550Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of penpulimab, anlotinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
penpulimabanlotinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04385550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385550.